Impact Of DPP4 Genotypes On GLP-1 Level AndResponse To Sitagliptin With Metformin TherapyIn Iraqi T2DM Patients

Abstract

Sitagliptin is one of numerous oral medications that cause the dipeptidyl  peptidase-4 (DPP-4) activity inhibition. Crucially, the DPP-4 enzyme is accountable for rapidly degrading and rendering inactive the incretin hormones. The action of these circulating incretins is prolonged by DPP-4 Inhibition via raising their levels and extending their half-life. Genetics significantly influences the progression of diabetes and determines who are susceptible to it. Our study aims to identify the association of (rs6741949) polymorphism for the gene encoding DPP4 with serum GLP-1 level and glycemic response for type 2 diabetics treated with sitagliptin in combination with metformin. High-Resolution Melting (HRM) analysis successfully identified SNP (rs6741949) in the study population, yet it exhibited no significant effect neither on serum GLP-1 level nor on the treatment response. However, the (rs6741949) genotypes were significantly associated with serum insulin and cholesterol levels, suggesting the potential role of the (rs6741949) variant in dyslipidemia regulation.